A clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s main focus is on its HCV NS5A inhibitor program, currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market.
Presidio Pharma
